公开(公告)号：US20070249592A1

公开(公告)日：2007-10-25

申请号：US11774995

申请日：2007-07-09

Applicant: Klaus Rudolf ,  Henri Doods ,  Stephan Mueller ,  Annette Zamponi ,  Philipp Lustenberger ,  Kirsten Arndt ,  Gerhard Schaenzle ,  Dirk Stenkamp ,  Rolf-Stefan Brickl

Inventor： Klaus Rudolf ,  Henri Doods ,  Stephan Mueller ,  Annette Zamponi ,  Philipp Lustenberger ,  Kirsten Arndt ,  Gerhard Schaenzle ,  Dirk Stenkamp ,  Rolf-Stefan Brickl

IPC: A61K31/517 ,  A61K31/5513

CPC classification number: A61K31/517

Abstract: The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, and to the use of said active compounds for the manufacture of a pharmaceutical composition intended to be used in this method.

Abstract translation: 本发明涉及一种治疗或预​​防接受阉割的男性热潮红的方法，例如， 由于前列腺癌治疗中的雄激素消除治疗，包括向患者施用有效量的选择的CGRP拮抗剂，以及使用所述活性化合物来制造预期用于该方法的药物组合物。

公开(公告)号：US20070244099A1

公开(公告)日：2007-10-18

申请号：US11757743

申请日：2007-06-04

Applicant: Klaus RUDOLF ,  Stephan MUELLER ,  Dirk STENKAMP ,  Philipp LUSTENBERGER ,  Alexander DREYER ,  Eckhart BAUER ,  Marcus SCHINDLER ,  Kirsten ARNDT ,  Henri DOODS

Inventor： Klaus RUDOLF ,  Stephan MUELLER ,  Dirk STENKAMP ,  Philipp LUSTENBERGER ,  Alexander DREYER ,  Eckhart BAUER ,  Marcus SCHINDLER ,  Kirsten ARNDT ,  Henri DOODS

IPC: A61K31/445 ,  A61K31/497 ,  A61K31/517 ,  A61K31/55 ,  A61P25/06 ,  A61P9/00

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D471/08 ,  C07D495/04

Abstract: CGRP antagonists of the formula of which the following are exemplary: (1) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(3,4-diethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl}-amide, (2) 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(3,4-diethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide.

Abstract translation: 具有下式的CGRP拮抗剂是示例性的：（1）4-（2-氧代-1,2,4,5-四氢-1,3-苯并二氮杂-3-基） - 哌啶-1-甲酸 - {（R）-1-（3,4-二乙基 - 苄基）-2- [4-（1-甲基 - 哌啶-4-基） - 哌嗪-1-基] -2-氧代 - 乙基} （2）4-（2-氧代-1,2,4,5-四氢-1,3-苯并二氮杂-3-基） - 哌啶-1-羧酸 - {（R）-1-（3,4- 乙基 - 苄基）-2- [4-（4-甲基 - 哌嗪-1-基） - 哌啶-1-基] -2-氧代 - 乙基} - 酰胺。

公开(公告)号：US20070099903A1

公开(公告)日：2007-05-03

申请号：US11550979

申请日：2006-10-19

Applicant: Stephan Mueller ,  Klaus Rudolf ,  Philipp Lustenberger ,  Gerhard Schaenzle ,  Dirk Stenkamp ,  Henri Doods ,  Kirsten Arndt

Inventor： Stephan Mueller ,  Klaus Rudolf ,  Philipp Lustenberger ,  Gerhard Schaenzle ,  Dirk Stenkamp ,  Henri Doods ,  Kirsten Arndt

IPC: A61K31/5513 ,  A61K31/517 ,  A61K31/454 ,  C07D413/14 ,  C07D403/14

CPC classification number: C07D401/14 ,  A61K31/551 ,  C07D413/14

Abstract: The present invention relates to the CGRP antagonists of general formula I wherein R1, R2, R3 and R4 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Abstract translation: 本发明涉及通式I的CGRP拮抗剂，其中R 1，R 2，R 3和R 4， SUP>如权利要求1中所定义，互变异构体，异构体，非对映异构体，对映异构体，其水合物，其混合物及其盐及其盐的水合物，特别是其生理上可接受的盐与无机或有机物 酸或碱，以及其中一个或多个氢原子被氘代替的通式I的那些化合物，含有这些化合物的药物组合物，其用途和制备方法。

公开(公告)号：US20070022945A1

公开(公告)日：2007-02-01

申请号：US11542987

申请日：2006-10-04

Applicant: Stephan Mueller

Inventor： Stephan Mueller

IPC: C30B23/00 ,  C30B25/00 ,  C30B28/12 ,  C30B28/14

CPC classification number: C30B23/00 ,  C30B23/025 ,  C30B29/36 ,  Y10S117/911

Abstract: Methods for producing silicon carbide crystals, seed crystal holders and seed crystal for use in producing silicon carbide crystals and silicon carbide crystals are provided. Silicon carbide crystals are produced by forcing nucleation sites of a silicon carbide seed crystal to a predefined pattern and growing silicon carbide utilizing physical vapor transport (PVT) so as to provide selective preferential growth of silicon carbide corresponding to the predefined pattern. Seed holders and seed crystals are provided for such methods. Silicon carbide crystals having regions of higher and lower defect density are also provided.

Abstract translation: 提供了用于制造碳化硅晶体和碳化硅晶体的碳化硅晶体，晶种保持器和晶种的制造方法。 通过将碳化硅晶种的成核位置强制为预定图案并利用物理气相传输（PVT）生长碳化硅以便提供对应于预定图案的碳化硅的选择性优先生长来生产碳化硅晶体。 为这种方法提供种子保持器和晶种。 还提供了具有更高和更低缺陷密度区域的碳化硅晶体。

公开(公告)号：US20060154921A1

公开(公告)日：2006-07-13

申请号：US11301422

申请日：2005-12-13

Applicant: Klaus Rudolf ,  Henri Doods ,  Stephan Mueller ,  Annette Zamponi ,  Philipp Lustenberger ,  Kirsten Arndt ,  Gerhard Schaenzle ,  Dirk Stenkamp ,  Rolf-Stefan Brickl

Inventor： Klaus Rudolf ,  Henri Doods ,  Stephan Mueller ,  Annette Zamponi ,  Philipp Lustenberger ,  Kirsten Arndt ,  Gerhard Schaenzle ,  Dirk Stenkamp ,  Rolf-Stefan Brickl

IPC: A61K31/5513

CPC classification number: A61K31/517

Abstract: The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, and to the use of said active compounds for the manufacture of a pharmaceutical composition intended to be used in this method.

Abstract translation: 本发明涉及一种治疗或预​​防接受阉割的男性热潮红的方法，例如， 由于前列腺癌治疗中的雄激素消除治疗，包括向患者施用有效量的选择的CGRP拮抗剂，以及使用所述活性化合物来制造预期用于该方法的药物组合物。

公开(公告)号：US20050245500A1

公开(公告)日：2005-11-03

申请号：US11071797

申请日：2005-03-03

Applicant: Gerald Roth ,  Philipp Lustenberger ,  Dirk Stenkamp ,  Stephan Mueller ,  Thorsten Lehmann-Lintz ,  Marcus Schindler ,  Leo Thomas ,  Ralf Lotz ,  Marco Santagostino

Inventor： Gerald Roth ,  Philipp Lustenberger ,  Dirk Stenkamp ,  Stephan Mueller ,  Thorsten Lehmann-Lintz ,  Marcus Schindler ,  Leo Thomas ,  Ralf Lotz ,  Marco Santagostino

IPC: A61K31/454 ,  A61K31/4709 ,  A61K31/4747 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  C07C235/74 ,  C07D205/04 ,  C07D207/08 ,  C07D207/20 ,  C07D209/08 ,  C07D211/42 ,  C07D211/46 ,  C07D211/48 ,  C07D211/52 ,  C07D211/58 ,  C07D211/62 ,  C07D221/20 ,  C07D263/56 ,  C07D295/092 ,  C07D295/135 ,  C07D401/12 ,  C07D413/02 ,  C07D417/02 ,  C07D43/02

CPC classification number: C07D207/08 ,  C07C235/74 ,  C07D205/04 ,  C07D207/20 ,  C07D209/08 ,  C07D211/42 ,  C07D211/46 ,  C07D211/48 ,  C07D211/52 ,  C07D211/58 ,  C07D211/62 ,  C07D221/20 ,  C07D263/56 ,  C07D295/088 ,  C07D295/135 ,  C07D401/12

Abstract: Compounds of formula I wherein the groups and residues A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.

Abstract translation: 式I化合物，其中基团和残基A，B，b，X，Y，Z，R 1，R 2，R 3， R 5a和R 5b具有权利要求1中给出的含义。 本发明还涉及含有至少一种本发明酰胺的药物组合物。 由于它们的MCH受体拮抗活性，根据本发明的药物组合物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症，贪食症，厌食症，食欲过盛和糖尿病。

公开(公告)号：US20050234101A1

公开(公告)日：2005-10-20

申请号：US11104889

申请日：2005-04-13

Applicant: Dirk Stenkamp ,  Stephan Mueller ,  Philipp Lustenberger ,  Thorsten Lehmann-Lintz ,  Gerald Roth ,  Klaus Rudolf ,  Marcus Schindler ,  Leo Thomas ,  Ralf Lotz

Inventor： Dirk Stenkamp ,  Stephan Mueller ,  Philipp Lustenberger ,  Thorsten Lehmann-Lintz ,  Gerald Roth ,  Klaus Rudolf ,  Marcus Schindler ,  Leo Thomas ,  Ralf Lotz

IPC: C07D213/30 ,  C07D213/38 ,  C07D213/74 ,  C07D213/75 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D409/10 ,  C07D409/14 ,  C07D451/06 ,  A61K31/4545 ,  A61K31/44 ,  A61K31/4439 ,  C07D41/02

CPC classification number: C07D213/30 ,  C07D213/38 ,  C07D213/74 ,  C07D213/75 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D409/10 ,  C07D409/14 ,  C07D451/06

Abstract: Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

Abstract translation: 具有MCH受体拮抗活性的炔烃化合物，其可用于制备用于治疗代谢紊乱和/或进食障碍，特别是肥胖和糖尿病的药物组合物。

公开(公告)号：US10753517B2

公开(公告)日：2020-08-25

申请号：US16052296

申请日：2018-08-01

Applicant: Stephan Mueller ,  Andreas Herbel ,  Carsten Haubold

Inventor： Stephan Mueller ,  Andreas Herbel ,  Carsten Haubold

IPC: F16L15/02 ,  F16L15/04 ,  F16L21/00 ,  F16L57/00 ,  F16L15/00 ,  F16L15/08 ,  F16L17/08

Abstract: A tubular connecting arrangement includes, a first tubular having a first shoulder and first threads, a second tubular having a second shoulder and second threads, a seal sealingly engagable to both the first shoulder and the second shoulder, an insert and a sleeve. The insert is attachable to the second tubular and configured to provide radial support to the second tubular. The sleeve threadably engagable with both the first threads and the second threads in response to being rotated in a same direction relative to both the first tubular and the second tubular such that the first shoulder and the second shoulder are moved toward one another to compress the seal therebetween without rotational movement of the first tubular relative to the second tubular.

公开(公告)号：US20180202238A1

公开(公告)日：2018-07-19

申请号：US15918061

申请日：2018-03-12

Applicant: Stephan Mueller ,  Volker Peters ,  Ingo Roders ,  Robert Buda ,  Rene Schulz ,  Henning Rahn

Inventor： Stephan Mueller ,  Volker Peters ,  Ingo Roders ,  Robert Buda ,  Rene Schulz ,  Henning Rahn

IPC: E21B17/00 ,  E21B17/02

Abstract: A wired pipe system includes a wired pipe segment having a first end and a second end, a first coupler in the first end and a second coupler in the second end and a transmission line disposed in the wired pipe segment between the first and second ends. The transmission line includes a transmission cable that includes an inner conductor and an insulating material disposed about the inner conductor as well as a a wire channel surrounding the insulating material and the inner conductor for at least a portion of a length of the transmission cable. The wire channel and the insulating material are mated together by at least one mating feature.

公开(公告)号：US09342258B2

公开(公告)日：2016-05-17

申请号：US14238495

申请日：2011-09-01

Applicant: Manfred Thanner ,  Nancy Amedeo ,  Stephan Mueller ,  Anthony Reipold

Inventor： Manfred Thanner ,  Nancy Amedeo ,  Stephan Mueller ,  Anthony Reipold

IPC: G06F3/00 ,  G06F3/06 ,  G06F12/08 ,  G06F13/16

CPC classification number: G06F3/0656 ,  G06F3/0611 ,  G06F3/0671 ,  G06F12/0862 ,  G06F13/1673 ,  G06F2212/6022

Abstract: An integrated circuit device comprising at least one memory interface module arranged to be operably coupled between at least one data storage device and a plurality of master devices within a data processing system. The at least one memory interface module comprises a plurality of buffers and at least one data access control module. The at least one data access control module being arranged to fetch data from the at least one data storage device in response to a received memory access request comprising a master device identifier, select at least one buffer based at least partly on the master device identifier of the received access request, and load the fetched data into the selected at least one buffer.

Abstract translation: 一种集成电路装置，包括至少一个存储器接口模块，其布置成可操作地耦合在数据处理系统内的至少一个数据存储设备和多个主设备之间。 所述至少一个存储器接口模块包括多个缓冲器和至少一个数据访问控制模块。 所述至少一个数据访问控制模块被布置成响应于包括主设备标识符的接收到的存储器访问请求从所述至少一个数据存储设备提取数据，至少部分地基于所述主设备标识符来选择至少一个缓冲器 所接收的访问请求，并将获取的数据加载到所选择的至少一个缓冲器中。